Please use this identifier to cite or link to this item:
Title: FGFR1 amplification or overexpression and hormonal resistance in luminal breast cancer: rationale for a triple blockade of ER, CDK4/6, and FGFR1
Filiation: Oncología-CNIO. Hospital Universitario de Fuenlabrada
Mesh: Receptor, Fibroblast Growth Factor, Type 1
Breast Neoplasms
Decs: Receptor Tipo 1 de Factor de Crecimiento de Fibroblastos
Neoplasias de la Mama
Issue Date: 12-Feb-2021
Citation: Breast Cancer Res.2021 Feb;(23)1:21
Abstract: FGFR1 amplification, but not overexpression, has been related to adverse prognosis in hormone-positive breast cancer (HRPBC). Whether FGFR1 overexpression and amplification are correlated, what is their distribution among luminal A or B HRPBC, and if there is a potential different prognostic role for amplification and overexpression are currently unknown features. The role of FGFR1 inhibitors in HRPBC is also unclear.
PMID: 33579347
Rights: info:eu-repo/semantics/openAccess
Appears in Collections:Hospitales > H. U. de Fuenlabrada > Artículos

Files in This Item:
File Description SizeFormat 
Breast Cancer Research.pdf2.49 MBAdobe PDFThumbnail

This item is licensed under a Creative Commons License Creative Commons